Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Completed
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2023
Locations: Center for Cancer Treatment & Prevention at Sacred Heart Hospital, Eau Claire, Wisconsin +12 locations
Conditions: Melanoma (Skin)
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
Completed
The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease. Pr... Read More
Gender:
ALL
Ages:
59 months and below
Trial Updated:
04/21/2022
Locations: Not set, Madison, Wisconsin +1 locations
Conditions: Pertussis
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: Gundersen Clinic, La Crosse, Wisconsin +7 locations
Conditions: Heart Failure, Myocardial Infarction
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
Completed
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2020
Locations: GSK Investigational Site, Madison, Wisconsin
Conditions: Influenza, Influenza Vaccines
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
Completed
The investigators are trying to find new methods to treat prostate cancer. The approach is to try to enhance patients' own immune response against the cancer. In this study, the investigators will be testing the safety of a vaccine that may be able to help the body fight prostate cancer. The vaccine, called pTVG-HP, is a piece of DNA genetic material that contains genetic code for a protein that is made by the prostate gland, called prostatic acid phosphatase (PAP). The vaccine will be given to... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin
Conditions: Prostate Cancer
Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
Completed
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract which includes Crohn's disease (CD) and ulcerative colitis (UC). A recent epidemiological investigation estimates that nearly 4 million people worldwide are affected and approximately 1.4 million of these cases occur in the United States. IBD can lead to debilitating symptoms, hospitalizations, decreased quality of life, frequent procedures and/or surgery. Treatment options consist of immunosuppress... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/18/2019
Locations: University of Wisconsin Hospital & Clinics, Madison, Wisconsin
Conditions: Inflammatory Bowel Disease (IBD)
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Terminated
This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from an antigen may help the body build an effective i... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/21/2017
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Efficacy of NicVAX in Smokers Who Want to Quit Smoking
Completed
The purpose of this study is to determine whether vaccination with NicVAX will result in a higher continuous abstinence rate than vaccination with placebo in smokers who want to quit smoking. In addition, two different formulations and dosing schedules will be studied, to select the dose and dosing schedule which generates the highest level of anti-nicotine antibodies. The primary study period is 12 months, which was extended by amendment to include up to 2 years of observations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2017
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Smoking Cessation
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Completed
The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00345579). No new recruitment will take place during this booster phase of the study. The Protocol Posting has been up... Read More
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
10/18/2016
Locations: GSK Investigational Site, Madison, Wisconsin +1 locations
Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Terminated
Primary objective: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment. Secondary objectives: Safety: To describe the safety profile in both treatment groups. Efficacy: To determine the objective clinical responses of patients in both treatment groups: complete response and partial response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2016
Locations: Not set, Madison, Wisconsin
Conditions: Melanoma, Cancer
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin +12 locations
Conditions: Lung Cancer
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
Completed
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild, moderate, or severe asthma. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine given as two 15 mcg injections. Both... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/08/2012
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: H1N1 Influenza Virus